Jaguar Health Submits Abstract for Crofelemer Trial in SBS-IF Patients

Jaguar Health, Inc. has submitted an abstract for consideration at the 2026 Digestive Disease Week conference, detailing preliminary findings from a trial of crofelemer in adult patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF). This marks another step in Jaguar's focus on intestinal failure, targeting orphan diseases such as SBS-IF and microvillus inclusion disease (MVID).

The study aims to address the need for reducing dependency on parenteral support in SBS-IF patients. Current treatments include life-sustaining intravenous nutrition, which bears significant health risks. Preliminary results from an ongoing trial in the UAE have shown promising reductions in parenteral support needs, reinforcing crofelemer's potential as a treatment option.

Jaguar Health continues to support trials across the US, EU, and Middle East to further explore crofelemer's efficacy. It holds Orphan Drug Designation for SBS and MVID, underscoring its commitment to addressing rare gastrointestinal disorders.